Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + bendamustine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Brentuximab vedotin + bendamustine is a combination regimen used primarily as salvage or induction therapy for relapsed or refractory classical Hodgkin lymphoma (cHL) and CD30-positive peripheral T-cell lymphoma (PTCL). Brentuximab vedotin is an antibody-drug conjugate consisting of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E. It targets CD30-expressing tumor cells, leading to cell death via microtubule disruption after internalization and release of MMAE. Bendamustine is a cytostatic alkylating agent that causes DNA crosslinking, resulting in apoptosis of cancer cells. The combination has shown high overall response rates as salvage therapy before autologous stem cell transplantation in cHL and PTCL patients[2][3][5][6].
- Brand names
- Adcetris (for brentuximab vedotin)Treanda (for bendamustine)
- Other names
- BV + BBBvbrentuximab vedotin and bendamustine
02
Targets
CD30 (CD30 antigen)DNA
Beyond the preview
Go deeper on brentuximab vedotin + bendamustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + bendamustine.